United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss MarkZacks Investment Research • 10/29/25
Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/29/25
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial ResultsBusiness Wire • 10/29/25
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/22/25
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025Business Wire • 10/15/25
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual MeetingBusiness Wire • 10/13/25
United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/23/25
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary FibrosisBusiness Wire • 09/19/25
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare ForumBusiness Wire • 09/16/25
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society CongressBusiness Wire • 09/12/25
United Therapeutics Corporation (UTHR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study WinSeeking Alpha • 09/04/25
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With ItInvestors Business Daily • 09/02/25
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary FibrosisBusiness Wire • 09/02/25